{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:05:38Z","timestamp":1789596338803,"version":"build-2803163510"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Encephalitis is characterized by brain parenchymal inflammation caused by infection or autoimmunity. There are limited recent data on how immunocompromised patients with encephalitis differ from the general encephalitis population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective study of 2 large medical institutions compares clinical characteristics and outcomes of immunocompromised and immunocompetent patients with all-cause encephalitis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 657 patients, 151 (23%) were immunocompromised. Immunocompromised patients were more likely to have an infectious etiology, comorbidities, inflammatory cerebrospinal fluid (CSF) profile, abnormal neuroimaging, and worse clinical outcomes as assessed by discharge Glasgow Outcome Scale (GOS) and in-hospital mortality (all P &amp;lt; .05). The most commonly identified etiologies in immunocompromised patients were herpes simplex virus (HSV) and varicella zoster virus. HSV accounted for similar proportions in the immunocompromised (18%) and immunocompetent (14%) groups, though it was more commonly associated with a CSF neutrophilia in the immunocompromised group (P = .001). Strikingly, &amp;gt;10% of immunocompromised patients with encephalitis had autoimmune causes, two-thirds of which were checkpoint inhibitor associated. Factors associated with poor GOS on discharge differed, with poorer outcomes in the infectious group associated with immunocompromised state and poorer outcomes in the autoimmune group associated with immunocompetent state.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Immunocompromised patients with encephalitis have differing causes, atypical clinical presentations, higher in-hospital mortality, and distinct factors associated with poor outcome as compared with immunocompetent patients. While HSV and opportunistic infections cause encephalitis in the immunocompromised, the diagnosis of autoimmune encephalitis should also be considered and can be checkpoint inhibitor associated.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofaf332","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T07:26:11Z","timestamp":1749626771000},"source":"Crossref","is-referenced-by-count":6,"title":["Encephalitis in Immunocompromised vs Immunocompetent Patients: A Comparative Study"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1626-6172","authenticated-orcid":false,"given":"Anna","family":"Kolchinski","sequence":"first","affiliation":[{"name":"Johns Hopkins Encephalitis Center, Department of Neurology, Johns Hopkins University, School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0991-0409","authenticated-orcid":false,"given":"Margaret","family":"Li","sequence":"additional","affiliation":[{"name":"Johns Hopkins Encephalitis Center, Department of Neurology, Johns Hopkins University, School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Habis","sequence":"additional","affiliation":[{"name":"Johns Hopkins Encephalitis Center, Department of Neurology, Johns Hopkins University, School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paris","family":"Bean","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Infectious Disease, McGovern Medical School, UTHealth, Science Center , Houston, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley N","family":"Heck","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Infectious Disease, McGovern Medical School, UTHealth, Science Center , Houston, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2095-0786","authenticated-orcid":false,"given":"John C","family":"Probasco","sequence":"additional","affiliation":[{"name":"Johns Hopkins Encephalitis Center, Department of Neurology, Johns Hopkins University, School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Hasbun","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Infectious Disease, McGovern Medical School, UTHealth, Science Center , Houston, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9335-7361","authenticated-orcid":false,"given":"Arun","family":"Venkatesan","sequence":"additional","affiliation":[{"name":"Johns Hopkins Encephalitis Center, Department of Neurology, Johns Hopkins University, School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"key":"2025070209013929100_ofaf332-B1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"key":"2025070209013929100_ofaf332-B2","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/QCO.0000000000000175","article-title":"Acute encephalitis in the immunocompromised individual","volume":"28","author":"Saylor","year":"2015","journal-title":"Curr Opin Infect Dis"},{"key":"2025070209013929100_ofaf332-B3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11910-021-01119-w","article-title":"Central nervous system infections in immunocompromised patients","volume":"21","author":"Pruitt","year":"2021","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2025070209013929100_ofaf332-B4","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1212\/WNL.0b013e3182752ceb","article-title":"Atypical manifestations and poor outcome of herpes simplex encephalitis in the immunocompromised","volume":"79","author":"Tan","year":"2012","journal-title":"Neurology"},{"key":"2025070209013929100_ofaf332-B5","doi-asserted-by":"crossref","first-page":"2300046","DOI":"10.2807\/1560-7917.ES.2024.29.6.2300046","article-title":"Steering committee and investigators. Encephalitis in HIV-negative immunodeficient patients: a prospective multicentre study, France, 2016 to 2019","volume":"29","author":"Landr\u00e9","year":"2024","journal-title":"Euro Surveill"},{"key":"2025070209013929100_ofaf332-B6","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1007\/s00415-023-11735-w","article-title":"Encephalitis in HIV-infected adults in the antiretroviral therapy era","volume":"270","author":"Reimer-Mcatee","year":"2023","journal-title":"J Neurol"},{"key":"2025070209013929100_ofaf332-B7","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/practneurol-2018-001923","article-title":"Autoimmune encephalitis (NMDAR antibody) in a patient receiving chronic post-transplant immunosuppression","volume":"18","author":"Randall","year":"2018","journal-title":"Pract Neurol"},{"key":"2025070209013929100_ofaf332-B8","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/cid\/cit458","article-title":"Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the International Encephalitis Consortium","volume":"57","author":"Venkatesan","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2025070209013929100_ofaf332-B9","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.mcna.2013.06.002","article-title":"Patients with immunodeficiency","volume":"97","author":"Hannaman","year":"2013","journal-title":"Med Clin North Am"},{"key":"2025070209013929100_ofaf332-B10","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.3390\/v13102018","article-title":"Recent issues in varicella-zoster virus latency","volume":"13","author":"Kennedy","year":"2021","journal-title":"Viruses"},{"key":"2025070209013929100_ofaf332-B11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0046-8177(98)90038-7","article-title":"Herpes simplex encephalitis (HSE) and the immunocompromised: a clinical and autopsy study of HSE in the settings of cancer and human immunodeficiency virus-type 1 infection","volume":"29","author":"Schiff","year":"1998","journal-title":"Hum Pathol"},{"key":"2025070209013929100_ofaf332-B12","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/jnnp-2013-307198","article-title":"Herpes simplex encephalitis in glioma patients: a challenging diagnosis","volume":"86","author":"Berzero","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2025070209013929100_ofaf332-B13","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1097\/CCM.0b013e3182374a34","article-title":"Herpes simplex virus encephalitis despite normal cell count in the cerebrospinal fluid","volume":"40","author":"Jakob","year":"2012","journal-title":"Crit Care Med"},{"key":"2025070209013929100_ofaf332-B14","doi-asserted-by":"publisher","first-page":"ciae391","DOI":"10.1093\/cid\/ciae391","article-title":"Absence of cerebrospinal fluid pleocytosis in encephalitis","author":"Habis","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025070209013929100_ofaf332-B15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1212\/01.wnl.0000195890.70898.1f","article-title":"CSF findings in 250 patients with serologically confirmed West Nile virus meningitis and encephalitis","volume":"66","author":"Tyler","year":"2006","journal-title":"Neurology"},{"key":"2025070209013929100_ofaf332-B16","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/ajcp\/105.3.364","article-title":"Predominance of neutrophils in the cerebrospinal fluid of AIDS patients with cytomegalovirus radiculopathy","volume":"105","author":"Granter","year":"1996","journal-title":"Am J Clin Pathol"},{"key":"2025070209013929100_ofaf332-B17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ijid.2017.04.010","article-title":"The clinical significance of neutrophilic pleocytosis in viral central nervous system infections","volume":"59","author":"Jaijakul","year":"2017","journal-title":"Int J Infect Dis"},{"key":"2025070209013929100_ofaf332-B18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0022-510X(98)00061-6","article-title":"Time course of chemokines in the cerebrospinal fluid and serum during herpes simplex type 1 encephalitis","volume":"157","author":"R\u00f6sler","year":"1998","journal-title":"J Neurol Sci"},{"key":"2025070209013929100_ofaf332-B19","author":"Love"},{"key":"2025070209013929100_ofaf332-B20","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1128\/JVI.76.6.2780-2788.2002","article-title":"Herpes simplex virus selectively induces expression of the CC chemokine RANTES\/CCL5 in macrophages through a mechanism dependent on PKR and ICP0","volume":"76","author":"Melchjorsen","year":"2002","journal-title":"J Virol"},{"key":"2025070209013929100_ofaf332-B21","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/14740338.2020.1738382","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"19","author":"Haugh","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"2025070209013929100_ofaf332-B22","doi-asserted-by":"crossref","first-page":"w20377","DOI":"10.4414\/smw.2020.20377","article-title":"Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature","volume":"150","author":"Stuby","year":"2020","journal-title":"Swiss Med Wkly"},{"key":"2025070209013929100_ofaf332-B23","doi-asserted-by":"crossref","first-page":"e440","DOI":"10.1111\/jdv.15756","article-title":"Encephalitis induced by immune checkpoint inhibitors in metastatic melanoma: a monocentric retrospective study","volume":"33","author":"Galmiche","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025070209013929100_ofaf332-B24","doi-asserted-by":"crossref","first-page":"e104169","DOI":"10.1371\/journal.pone.0104169","article-title":"Encephalitis hospitalization rates and inpatient mortality in the United States, 2000\u20132010","volume":"9","author":"George","year":"2014","journal-title":"PLoS One"},{"key":"2025070209013929100_ofaf332-B25","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1086\/648419","article-title":"Infectious encephalitis in France in 2007: a national prospective study","volume":"49","author":"Mailles","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2025070209013929100_ofaf332-B26","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.antiviral.2006.04.002","article-title":"Herpes simplex encephalitis: adolescents and adults","volume":"71","author":"Whitley","year":"2006","journal-title":"Antiviral Res"},{"key":"2025070209013929100_ofaf332-B27","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/jnnp.63.3.321","article-title":"Herpes simplex encephalitis treated with acyclovir: diagnosis and long term outcome","volume":"63","author":"McGrath","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2025070209013929100_ofaf332-B28","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1086\/341405","article-title":"Outcome of and prognostic factors for herpes simplex encephalitis in adult patients: results of a multicenter study","volume":"35","author":"Raschilas","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2025070209013929100_ofaf332-B29","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1086\/380458","article-title":"Severe West Nile virus disease in healthy adults","volume":"38","author":"Emig","year":"2004","journal-title":"Clin Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaf332\/63465711\/ofaf332.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/7\/ofaf332\/63465711\/ofaf332.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/7\/ofaf332\/63465711\/ofaf332.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T13:01:47Z","timestamp":1751461307000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf332\/8160120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,6,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf332","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,6,11]]},"article-number":"ofaf332"}}